AGRX - Agile Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1350
-0.4450 (-12.43%)
As of 12:07PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.5800
Open3.0800
Bid3.1300 x 3200
Ask3.1400 x 1000
Day's Range3.0300 - 3.2400
52 Week Range0.3500 - 4.7650
Volume5,159,260
Avg. Volume3,226,721
Market Cap218.823M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
EPS (TTM)-0.3870
Earnings DateFeb 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.20
  • GlobeNewswire

    Agile Therapeutics Announces Pricing of $45 Million Underwritten Public Offering of Common Stock

    Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $45 million. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions.

  • Benzinga

    The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptose Biosciences ...

  • GlobeNewswire

    Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

    Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. Agile Therapeutics intends to grant the underwriters a 30-day option to purchase an additional fifteen percent of the shares of common stock offered in the public offering.

  • GlobeNewswire

    Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

    Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company’s Lead Product Candidate, Receives FDA Approval.

  • GlobeNewswire

    FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin

    Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI

  • Benzinga

    The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...

  • Benzinga

    Agile Finalizes $35M Term Loan Facility As Twirla PDUFA Date Looms

    Agile Therapeutics Inc (NASDAQ: AGRX) shares are advancing Tuesday after the company announced clinching of a term loan facility. The micro-cap biotech that focuses on women's health said late Monday it has finalized a senior secured term loan credit facility with Perceptive Advisors to provide it funding up to $35 million. The facility will disburse term loans in three tranches.

  • GlobeNewswire

    Agile Therapeutics, Inc. Enters into up to $35 Million Loan Facility with Perceptive Advisors

    Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit  facility with Perceptive Advisors to provide Agile with up to $35 million through term loans in three tranches. $5 million was funded today after the satisfaction of customary closing conditions, $15 million will be available if Twirla® is approved by the U.S. Food and Drug Administration (“FDA”), and $15 million will be available upon the achievement of certain revenue milestones.

  • Benzinga

    Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

    Biotech stocks have come under some selling pressure in the new year. However, January did witness some strong stock-specific upward moves, especially with stocks leveraged to the Wuhan coronavirus epidemic. ...

  • 5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts
    Kiplinger

    5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts

    When searching for big rewards, look no further than biotech stocks.Just be prepared for big risk, too.Biotechs offer gobs of price potential. That's because unlike many companies that can slowly but steadily build up their businesses over time, the survival of biotechnology companies (especially early on) hinges on just a few trials of their developing treatments. Eventual approval of the drug means life-sustaining revenues for the company, so positive trial news can send shares skyrocketing. Setbacks, however, can spark an exodus.While it's impossible for regular investors to gauge what's going on in testing labs, you can give yourself a small leg up by paying attention to the analysts who cover the biotechnology industry. If you find a stock that's mostly surrounded by bulls, that might be a signal that something rewarding is around the bend.Here are five biotech stocks that have a "Strong Buy" consensus analyst rating and have potential catalysts right around the corner. We've used TipRanks' Smart Score system to identify this health-care short list. Also remember that biotechnology stocks come with a considerable amount of risk, and that sharp drops are not uncommon. Consider using only a small allocation from the portion of your portfolio dedicated to aggressive investments. SEE ALSO: 10 High-Quality, High-Growth Stocks to Buy

  • The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences
    Zacks

    The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

    The Zacks Analyst Blog Highlights: Agile Therapeutics, Air Industries, Dermira, Microbot Medical and Cassava Sciences

  • Buy Multibagger Stocks as Odds of a Rally Are High in 2020
    Zacks

    Buy Multibagger Stocks as Odds of a Rally Are High in 2020

    Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

  • The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold
    Zacks

    The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold

    The Zacks Analyst Blog Highlights: Agile Therapeutics, Ares Capital, Cable One, Evolution Petroleum and Royal Gold

  • Here's How to Play Stocks as US-Iran Tensions Mount
    Zacks

    Here's How to Play Stocks as US-Iran Tensions Mount

    Since we do expect at least short-term volatility, low-beta stocks are the best choice as they are less correlated to the index and thus tend to be less volatile.

  • GlobeNewswire

    Agile Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco

    PRINCETON, N.J., Jan. 06, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the company will present at the 38th Annual J.P..

  • Benzinga

    The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 2) Agile Therapeutics Inc (NASDAQ: AGRX (announced the ...

  • GlobeNewswire

    Agile Therapeutics Strengthens Commercial Leadership Team

    PRINCETON, N.J., Jan. 02, 2020 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Kimberly Whelan as Vice President of.

  • Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options
    Zacks

    Implied Volatility Surging for Agile Therapeutics (AGRX) Stock Options

    Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.

  • GlobeNewswire

    Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco

    PRINCETON, N.J., Dec. 19, 2019 -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has scheduled a company presentation at Biotech.

  • Hedge Funds Have Never Been More Bullish On Agile Therapeutics Inc (AGRX)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Agile Therapeutics Inc (AGRX)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]

  • Benzinga

    The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • GlobeNewswire

    Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period

    Agile Therapeutics, Inc. (AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Twirla® (levonorgestrel/ethinyl estradiol) transdermal system, an investigational combined hormonal contraceptive patch, from November 16, 2019 to February 16, 2020. On October 30, 2019, the FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) met to discuss the benefits and risks of Twirla and voted 14 to 1, with one abstention, that the benefits of Twirla (AG200-15) in the prevention of pregnancy outweigh the risks to support approval.

  • RBC: 3 Stock Picks Set to Soar 30%+
    TipRanks

    RBC: 3 Stock Picks Set to Soar 30%+

    Global investment bank, RBC Capital, is one of the finance world’s heavy hitters. It is the 5th largest in North America, and with 70 offices in 15 countries around the world, it has a stellar reputation. This international reputation and the financial clout that comes with it, naturally attracts top talent, and top talent can bring home the bacon, so to speak. It is no wonder then that RBC leads TipRanks’ list of Top Performing Research Firms.With this in mind, we decided to take a look at some of the recent stock recommendations from RBC analysts, specifically ones with potential for 30%+ gains ahead.Agile Therapeutics (AGRX)Agile Therapeutics shares took a nosedive in late October after briefing documents released by the FDA expressed concern regarding the “effectiveness in proportion to its safety,” of Twirla, the company’s contraceptive patch, ahead of an AdCom review. As it happens, the review panel voted in favor of approval, which coincidentally, sent the stock skyrocketing.Following the AdCom’s positive outcome, RBC surveyed physicians to better understand the experts’ view on Twirla. The results echoed those of the AdCom, and with the PDUFA set for November 16, the impression is that Twirla will most likely be granted approval by the FDA.RBC analyst Randall Stanicky noted, “We could see approval this week or alternatively a potential ~3month delay as FDA works through labeling; either way we think shares at these levels show attractive near-term upside… Our survey of 40 OB/GYNs was surprisingly bullish on desire for Twirla as a contraceptive option; this increases our conviction that there is a place for it in the market.”As a result, Stanicky reiterates a Buy rating on AGRX along with a $5.00 price target, which implies a whopping upside of 130% from current levels. (To watch Stanicky’s track record, click here)How does Stanicky's bullish bet weigh in against the Street? It appears the analyst is not the only one enthusiastic on this healthcare stock, with TipRanks analytics demonstrating AGRX as a Strong Buy. This breaks down into 5 "buy" ratings in the last three months. With a return potential of over 100%, the stock’s consensus target price stands at $4.50. (See Agile stock analysis on TipRanks)Rapid7 (RPD)Cyber-security firm, Rapid7, provides data and analytics software to help organizations keep their networks safe from malicious cyber threats. Basically, it does what it says on the tin and reduces risk across a connected environment.Last week, Rapid7 delivered stronger quarterly results than expected, with annualized recurring revenue (ARR) growing by 43% on top of 17% customer growth. Overall, the company posted earnings of one cent per share on revenue of $83.16 million, beating the loss of 3 cents and revenue of $80.12 million analysts expected. Therefore, the company has now raised 2019 revenue guidance from $319 million to $323.5 million.Citing Rapid7 as a favorite SMID-cap, RBC’s 5-star analyst Matthew Hedberg believes that although estimates have gone higher, they still look beatable. Hedberg noted, “ARR growth is the key metric, as management expects it to remain at or above 30% through 2020. While the stock has performed well, we continue to believe it represents an attractive investment… In addition to new customer additions, we believe 2020 should see the cross-sale of additional products like InsightIDR and InsightAppSec and longer-term InsightConnect. This value generation was shown in ARR per customer, which grew 22% y/y… Our estimates move higher, but we still believe upside remains through 2020…”This has led Hedberg to keep his Buy rating along with a price target of $81.00. With RPD currently trading at $51.08, this provides upside of about 60%. (To watch Hedberg’s track record, click here).Looking at the consensus breakdown, the cyber-security firm has amassed 8 Buys and 1 Hold in the last three months, making Rapid7 a Strong Buy. The average stock-price forecast is $65.50. Not quite as bullish as Hedberg, this target still provides upside of 28% from its current price. (See Rapid7 price targets and analyst ratings on TipRanks)Aprea Therapeutics (APRE)Aprea Therapeutics is a Boston, Massachusetts-based biopharma focused on developing and bringing to market novel cancer therapeutics that reactivate mutant tumor suppressor protein p53. Aprea’s main drug candidate is APR-246, a small molecule in clinical development designed to treat various forms of cancer with TP53 mutations. These are found in half of all cancers. Through its unique design, APR-246 is able to restore immune defenses and promote apoptosis of cancer cells.The company will present updated data from its phase II trial in December, and it believes APR-246 will be a first-in-class therapy if approved by regulators.RBC’s Gregory Renza agrees, saying, “We believe APRE’s small molecule p53 reactivator pipeline in oncology, led by APR-246, has ample potential given the data to date and catalyst setup expected over the year. We see APRE emerging as a competitive player in the oncology space, especially in severe TP53 populations where unmet need is high, and believe in its potential for long-term share appreciation as the programs continue to de-risk… If approved, we see prospects of $800M WW peak sales in MDS at a ~35% POS, driving 2/3 of our valuation.”Renza initiated coverage with a bullish call and set a price target of $33.00, indicating upside of over 32%. (To watch Renza’s track record, click here)It’s a tad quiet when it comes to analyst coverage, with only two other analysts currently providing ratings for APRE, both recommending a Hold. With an average price target of $26.33 providing a modest 5% upside from its current price, the biopharma newbie ranks as a Moderate Buy. (See Aprea price targets and analyst ratings on TipRanks)

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...

  • Agile (AGRX) Stock Surges Over 370%, What’s Next?
    TipRanks

    Agile (AGRX) Stock Surges Over 370%, What’s Next?

    Agile therapeutics (AGRX) has had a, shall we say, crazy week in the market. On Monday, October 28, its share price was sent on a downward spiral following the release of negative briefing documents by the FDA which expressed concerns about its contraceptive patch, Twirla. The FDA’s main points of concern regarded Twirla’s “effectiveness in proportion to its safety,” as the estimated Pearl Index (PI) in the Phase 3 ATI-CL23 study exceeded the required level. Furthermore, it rejected Agile’s proposal of a limitation of use label following results which showed 2x pregnancy rate in obese women.Well, what a difference two days makes. On Wednesday, the AdCom review caused a major upset, with a 14-1 vote in favor of supporting Twirla for approval. This sent the stock price soaring, with gains of over 370% since.But how much further can the stock grow? H.C. Wainwright’s Oren Livnat may have the answer. Following the positive outcome, the analyst reiterated a Buy rating on AGRX stock, while raising his price target to $5 (from $4), which implies about 185% upside from current levels. (To watch Livnat's track record, click here)Livnat admits the FDA’s negativity initially took him by surprise, believing the FDA’s alarmist concerns were unjustified. Still, the analyst thinks there is much left to work out between Agile and the FDA, not least the product’s label. The AdCom panel agreed the label must include a “clear Limitation of Use (LOU) for obese women with BMI over 30 due to lower contraceptive efficacy." Most on the panel are against a stricter contraindication in obese women, but the FDA might want to go that way, regardless.“Of course, there remains material risk here, as the AdCom vote is just a non-binding recommendation, and approval clearly requires a total 180degree turn in agency thinking, and we’d be surprised if final approval is reached on the November 16 PDUFA just two weeks away. However, specific timing aside, we have to think Twirla’s ultimate approval is quite likely now, so we increase our probability of success to 70% from 60%,” Livnat said.Maxim's Jason McCarthy also believes the market over reacted to the briefing document, yet amidst the new found optimism, posted a note of caution, saying, “The PDUFA is 11/16 and it is important to note that while FDA typically follows the Adcom's recommendation, it does not always do so, which really must be considered since the FDA briefing docs appeared to be against approval… We see the probability favoring Agile, but this could be considered aggressive and as such would say that risk averse investors may want to step aside.” The analyst keeps his price target at $3.00. While not quite as bullish as Livnat, this still gives AGRX upside of over 70%.Not many sectors offer the potential for such big time gains like biotech. Especially when you’re looking at smaller clinical-stage names such as Agile therapeutics. After all, the thrill of getting a big-time approval can send a stock's price surging. Conversely, one mishap can send shares crashing. That said, Wall Street’s confidence on AGRX speaks for itself; the stock has received a 5 'buy' ratings in the last three months. Meanwhile, the $4.50 consensus price target suggests a potential upside of 160% from the current share price. (See Agile stock analysis on TipRanks)